Meet the Proteona team at the 9th Mildred Scheel Cancer Conference in Bonn, Germany
Innovative genomic and proteomic analysis platform for Immuno-Oncology and Single Cell BioMedical Applications
Dr Andreas Schmidt, the CEO of Proteona, will attend the 9th Mildred Scheel Cancer Conference from the 15th to the 16th May, 2019. The biennial conference, this year taking place in Bonn, Germany, focuses on important topics such as cancer immunotherapy and personalized medicine.
Dr Schmidt will be available during the conference to discuss how single cell analysis using Proteona’s ESCAPE platform can help advancing novel immunotherapies and understanding patient response, such as CAR T-cell immunotherapy.
For media queries, please contact:
Dr Andreas Schmidt
Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services.